Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1373/clinchem.2019.306977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing hand motor function in chronic immune-mediated neuropathies: a proof-of-concept study using a data glove.
J Neuroeng Rehabil
December 2024
Department of Neurology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Background: Chronic immune-mediated neuropathies are clinically heterogeneous and require regular, objective, and multidimensional monitoring to individualize treatment. However, established outcome measures are insufficient regarding measurement quality criteria (e.g.
View Article and Find Full Text PDFEfficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.
Ann Med
December 2024
Department of Medical and Surgical Science, Universidad de las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Article Synopsis
- - Dupilumab is a new medicine that helps people with severe nasal issues and asthma, and this study looked at how it works for patients who have or haven’t used similar medicines before.
- - The study involved 42 patients, most of whom had asthma, and measured their symptoms and health after 12 months of using dupilumab.
- - Results showed that dupilumab made a big difference in improving patients' symptoms, reducing nasal polyp size, and making overall health better for everyone, no matter their previous treatment history.
The Disconnect between Clinical Guidelines and Reality: The Case of Trastuzumab.
Cancer Epidemiol Biomarkers Prev
October 2024
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
HER2-positive breast cancer accounts for 10% to 20% of all breast cancer diagnoses. The mAb trastuzumab is crucial in treating this disease, significantly improving survival outcomes. Despite its inclusion in the World Health Organization's Model List of Essential Medicines, access to trastuzumab remains limited worldwide.
View Article and Find Full Text PDFA randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
Clin Exp Rheumatol
August 2024
Department of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.
Objectives: The type I interferon pathway is a promising target for treatment of patients with systemic sclerosis (SSc). Here, we describe the design of a multinational, randomised phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis (DAISY).
Methods: DAISY includes a 52-week double-blind, placebo-controlled treatment period, a 52-week open-label active treatment period, and a 12-week safety follow-up period.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Lancet
August 2024
Novartis Pharma, Basel, Switzerland. Electronic address:
Background: Sjögren's disease is a chronic autoimmune disease with an unmet need for targeted therapies. The aim of the TWINSS study is to evaluate the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in patients with active Sjögren's disease.
Methods: This randomised, double-blind, placebo-controlled, phase 2b study, conducted at 71 sites in 23 countries, enrolled patients aged 18 years or older fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) 2016 criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!